Clinical trials: Analgesics, Opioid
Pain, Postoperative, Analgesics, Opioid
Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy
The clinical study described in this Clinical Investigation Plan (CIP) will be completed in two stages, Phase I and Phase II. The results of Phase I will confirm patient use of InCaveo's EOA system with integrated mobile CBT but…
- Trial name
- P1RESPECT (NCT04836169)
- Testing
- InCaveo's EOA system with integrated mobile CBT
- Volunteers
- 30 people
- Sponsor
- InCaveo
Pain, Analgesics, Opioid
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain
The purpose of this study was to characterize the steady-state pharmacokinetic (metabolism and action) profile of OROS hydromorphone HCI (slow release) in patients who required opioid therapy on a daily basis for chronic pain…
- Trial name
- NCT00410878
- Testing
- OROS Hydromorphone HCI (slow release)
- Volunteers
- 22 people
- Sponsor
- Alza Corporation, DE, USA
Standard Opioid Analgesic Treatment of Cancer-related Chronic Pain.
Efficacy and Safety of FITpatch Compared to Standard Opioid Treatment in Cancer Pain (FT-015-IN)
Primary objectives: To determine non-inferiority of FITpatch with regard to efficacy compared to standard opioid treatment To assess the safety of FITpatch compared to standard opioid treatment Secondary objectives: To assess the…
- Trial name
- NCT00279344
- Testing
- Fentanyl (Matrifen)
- Volunteers
- 220 people
- Sponsor
- Nycomed
Pain, Analgesics, Opioid
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
The purpose of this study was to demonstrate the clinical equivalence of hydromorphone and morphine (immediate-release [IR] and sustained-release [SR] formulations) using the "worst pain in the past 24 hours" item of the Brief…
- Trial name
- NCT00410540
- Testing
- OROS hydromorphone HCL ; Morphine sulfate
- Volunteers
- 202 people
- Sponsor
- Alza Corporation, DE, USA
Pain, Analgesics
A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain
The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone in patients with chronic non-malignant pain converting from other strong oral or transdermal…
- Conditions
- Pain, Analgesics, Opioid
- Trial name
- NCT00410644
- Testing
- OROS Hydromorphone HCI
- Volunteers
- 463 people
- Sponsor
- Alza Corporation, DE, USA
Pain, Analgesics, Opioid
Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)
The purpose of study was to characterize the safety and tolerability of long-term repeated dosing of OROS hydromorphone controlled release tablets (8,16,32, and 64 mg) in patients with chronic cancer pain or chronic non-malignant…
- Trial name
- NCT00410748
- Testing
- OROS hydromorphone HCI CR
- Volunteers
- 388 people
- Sponsor
- Alza Corporation, DE, USA
Analgesics, Opioid, Pain
Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain
The primary purpose of this study was to characterize the pain control achieved with long-term repeated dosing of OROS hydromorphone (slow release) in patients with chronic cancer pain and the secondary purpose was to…
- Trial name
- NCT00410787
- Testing
- OROS hydromorphone HCI (slow release)
- Volunteers
- 68 people
- Sponsor
- Alza Corporation, DE, USA
Analgesics, Opioid, Pain
A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain
The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone HCI (slow release) in patients with chronic cancer pain converting from other strong oral or…
- Trial name
- NCT00411034
- Testing
- OROS Hydromorphone HCI
- Volunteers
- 463 people
- Sponsor
- Alza Corporation, DE, USA